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Abstract
Background: Vitamin D level is inversely associated with tuberculosis (TB) and diabetes (DM). Vitamin D could be a
mediator in the association between TB and DM. We examined the associations between vitamin D, TB and DM.
Methods: Consecutive adults with TB and sex- and age-matched volunteers were included in a case-control study
in Dar es Salaam, Tanzania. Glycemia and total vitamin D (25(OH)D) were measured at enrolment and after TB
treatment in cases. The association between low 25(OH)D (<75 nmol/l) and TB was evaluated by logistic regression
adjusted for age, sex, body mass index, socioeconomic status, sunshine hours, HIV and
an interaction between low 25(OH)D and hyperglycemia.
Results: The prevalence of low 25(OH)D was similar in TB patients and controls (25.8 % versus 31.0 %; p = 0.22). In
the subgroup of patients with persistent hyperglycemia (i.e. likely true diabetic patients), the proportion of
patients with low 25(OH)D tended to be greater in TB patients (50 % versus 29.7 %; p = 0.20). The effect
modification by persistent hyperglycemia persisted in the multivariate analysis (pinteraction = 0.01).
Conclusions: Low 25(OH)D may increase TB risk in patients with underlying DM. Trials should examine if
this association is causal and whether adjunct vitamin D therapy is beneficial in this population.
Keywords: Stress-induced hyperglycemia, Transient hyperglycemia, Tuberculosis, Vitamin D, Diabetes
Background
Diabetes mellitus (DM) triples the risk of tuberculosis
(TB) and the global increase of DM in developing
countries is expected to have an important impact on
TB incidence [1, 2]. Several studies have shown an
association between low blood levels of vitamin D with
both TB and DM [3–5]. Vitamin D is mainly generated in
the skin exposed to sunlight and, to a lower extent,
through dietary intake [6]. Vitamin D is usually measured
as total blood level of 25 hydroxyvitamin D (25(OH)D)
which represents vitamin D bound to albumin and
vitamin D binding proteins (VDBP) as well as free
vitamin D and does not represent only the levels of
the free, active metabolite (1,25(OH)2D) which requires
conversion from 25(OH)D. The free biological active
vitamin D, 1,25(OH)2D, has a short half-life and, therefore,
25(OH)D measurement is more representative of the
vitamin D status of an individual. However, the level
of the free active vitamin D can be modifiedby the
level of binding proteins as well as by the binding
affinity of VDBP which is affected by genotype [7].
Vitamin D deficiency was first described as the cause
of rickets and osteomalacia. However, the vitamin D
receptor is expressed in most cells in the body and vitamin
D seems to have an effect on a number of other health
outcomes [6]. The association between type 2 DM and
low vitamin D has been described in several cross-
sectional and prospective studies and a meta-analysis of
21 prospective studies showed an inverse association be-
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particularly when 25(OH)D was <50 nmol/l [8]. Vitamin
D affects pancreatic β-cell function, boosts the antimicro-
bial activity of human macrophages against Mycobacter-
ium tuberculosis, and modulates adaptive response [9].
Building on these findings, it was suggested that a low
blood level of vitamin D could mediate some of the asso-
ciation between DM and TB [10]. A cross-sectional Indian
study confirmed the association between severe vitamin D
deficiency (<25 nmol/l), TB and DM while another study
conducted in China did not [11, 12].
A trial showed that vitamin D supplementation acce-
lerates the resolution of inflammatory responses during
TB treatment and may be used as a host-directed the-
rapy [13]. However, the role of adjunctive vitamin D on
TB outcome remains uncertain as several randomized
clinical trials of vitamin D supplementation did not
show a beneficial effect on TB outcome or mortality
[14–18]. Vitamin D supplementation might have a role
in the prevention and treatment of TB in targeted
subgroups of patients with low vitamin D levels, such
as diabetic patients.
In this study, we aimed to describe first, the determi-
nants of low vitamin D level among healthy controls and
TB patients and, second, the association between TB,
vitamin D, and the presence and persistence of hypergly-
cemia in an African equatorial population.
Methods
Study design and setting
This case-control study with longitudinal follow-up of
cases was part of a study on the association between
TB and DM [19]. In this sub-study, TB patients were
recruited between February and December 2013 and
followed up for a median time of 5.8 months (IQR
4.7–9.9) after the start of anti-TB treatment. Controls
were recruited between March and September 2013 and
did not have follow-up visits. Glucose and 25(OH)D were
measured in blood collected at baseline from cases (88 %
before onset of TB treatment) and controls, and in blood
collected at follow-up from cases (54 % still under TB
treatment). The study was carried out in Kinondoni,
the most populated District of Dar es Salaam. Patients
were recruited in Mwananyamala Regional Hospital and
connected health facilities (Sinza Hospital, Magomeni
Health Centre, Tandale Dispensary). Dar es Salaam is
located at a latitude of −6.81° and longitude of 39.28°
which ensures a good ability of sunlight to synthesize
vitamin D [6].
Study participants
Cases
Consecutive adult patients (age ≥18 years; living in
Kinondoni District) presenting in the participating hospitals
with new active TB diagnosed by the National TB and
Leprosy Control Programme (NTLP) were screened for
study inclusion. TB diagnosis was based on sputum smear
microscopy, chest X-ray (read by an experienced radio-
logist), clinical evidence of TB and decision by the clin-
ician to treat with a full-course of anti-TB therapy [20].
TB patients were classified as pulmonary smear-positive,
smear-negative or extrapulmonary according to NTLP
guidelines [21]. TB patients were treated for 6 months
with a standard regimen or longer if necessary [20, 22].
Controls
We used frequency matching on sex and age (10-year
age groups) to select controls among adults accompany-
ing patients (other than the one included in the study)
to the outpatient departments and living in Kinondoni
District. Exclusion criteria were a biological relationship
to case, TB history, symptoms or signs of TB, other acute
infection or major trauma within the last 3 months.
Study procedures
Demographic characteristics, DM history and symptoms,
socioeconomic status (SES; indicators of education,
occupation, wealth using factor analysis), smoking (ever
daily smoking), and alcohol misuse (≥three drinks per
day or ≥ six drinks per occasion) were obtained. Daily
sunshine hours’ data were provided by the Tanzanian
meteorological agency. Data were entered directly into
an open data kit in a personal digital assistant with
real-time error, range and consistency checks [23]. Parti-
cipants were screened for HIV infection according to the
national algorithm (rapid immune-chromatographic test
(Alere Determine™ HIV-1/2) confirmed by a second rapid
test (Trinity Biotech Uni-gold™ Recombigen® HIV-1/2)).
Total 25 hydroxyvitamin D measurement
Serum was kept at −80 °C within 6 h of blood draw and
blood 25(OH)D level was assessed by electrochemolu-
minescence immunoassay (Cobas® 8000, Roche Diagnos-
tics) in the Institute of Clinical Chemistry at the
University Hospital of Zurich in Switzerland. Low blood
vitamin D status was defined as a 25(OH)D <75 nmol/l
and vitamin D deficiency as a 25(OH)D <50 nmol/l [6, 24].
Of note, no patient received vitamin D replacement
therapy.
Hyperglycemia screening
Blood glucose testing was conducted after an overnight
fast of ≥8 h (fasting capillary glucose, FCG) and 2-h glu-
cose in an oral glucose tolerance test (2-hCG; standard
75-g OGTT; GlucoPlus™, Diabcare, plasma-calibrated
glucometer which accuracy conformed to the Inter-
national Standardization Organization guidelines) [25].
Abnormal glycemic results (FCG ≥5.6 mmol/l or 2-hCG
≥7.8 mmol/l) were confirmed by repeat testing 2 to
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5 days later. For safety reasons, 2-hCG testing was omit-
ted if FCG was ≥11.1 mmol/l and DM was diagnosed.
Hyperglycemia refers to patients with repeated FCG
≥6.1 mmol/l and/or 2-hCG ≥7.8 mmol/l according to
WHO [26]. Persistent hyperglycemia was defined based
on hyperglycemia measured at enrolment and confirmed
at follow-up and is considered a proxy for pre-existing
DM. Hyperglycemia detected at enrolment only is more
likely to reflect stress hyperglycemia as a result of TB
[19]. Participants diagnosed with DM (FCG >7 mmol/l
or 2-hCG >11 mmol/l) were referred to the local DM
clinic, but none was started on DM treatment. Indeed,
they all had a fasting glycemia below 10 mmol/l and it is
the usual practice in Tanzania not to treat these patients.
Data analysis
Characteristics of TB patients were compared to controls.
Factors associated with low 25(OH)D were identified by
comparison with participants with a normal level. Diffe-
rences were tested with Wilcoxon-Mann-Whitney and
chi-square tests. The independent association between
low 25(OH)D and TB, as well as between persistent
hyperglycemia (suggestive of underlying DM) and TB, was
evaluated by multivariate logistic regression. We also
assessed the interaction between low 25(OH)D and per-
sistent hyperglycemia (suggestive of underlying DM) to
examine if the association between TB and vitamin D
might differ according to underlying DM status.
To assess the combined effect of low 25(OH)D and
hyperglycemia, a 4-level categorical variable reflecting
the combination of underlying DM and vitamin D status
was used as predictor variable in the logistic regression
models. Covariates included age, sex, body mass index
(BMI), SES, mean daily sunshine hours during the month
of enrolment, HIV status.
Statistical analyses were performed using Stata software
(StataCorp, College Station, TX, USA, version 12) and
GraphPad Prism 6. P values <0.05 were considered as
significant.
Results
Study sample
At enrolment, 280 TB patients and 358 controls had
blood sampled for 25(OH)D and glucose measurement.
The final study sample consisted of 167 TB cases with
follow-up information and 358 controls, all of whom
had complete information on glycemic status, 25(OH)D
and relevant covariates (Fig. 1). Characteristics of the
study sample are described in Table 1. Compared to
controls, TB patients were more often HIV-infected,
previously known for DM and had a lower BMI. At
enrolment, hyperglycemia was more common in TB
patients than in controls. There was no longer a difference
when looking at persistent hyperglycemia, i.e. excluding
patients with stress hyperglycemia secondary to TB infec-
tion [19]. Among TB patients with hyperglycemia at
enrolment, 34 % (N = 13) had a FCG and/or 2-hCG in the
DM range and 68 % had a normal glycemia after TB treat-
ment although none of them received treatment for DM
and only three had lifestyle counselling (Additional file 1:
Figure S1). Blood 25(OH)D increased during TB treat-
ment (mean ± SD increase 6.5 ± 21 nmol/, p = 0.03) inde-
pendently of ongoing TB treatment at the time of
measurement (Fig. 2). Correspondingly, the prevalence of
low 25(OH)D decreased (25.8 % versus 20.4 %, p < 0.001).
Fig. 1 Flow chart of study participants. Abbreviation: TB: tuberculosis
Boillat-Blanco et al. BMC Infectious Diseases  (2016) 16:626 Page 3 of 9
Characteristics and glycemic and vitamin D status of
TB patients with and without follow-up were compa-
rable, except for underweight and male sex being more
common among subjects without follow-up (Additional
file 2: Table S1).
Correlates of low 25(OH)D level
In the control group, low 25(OH)D was more common
in women than in men, but less common in HIV
infected persons. In TB patients, low 25(OH)D was asso-
ciated with underlying DM (assessed as either a previous
DM diagnosis or as persistent hyperglycemia at enrol-
ment and at follow up; Table 2). Level of 25(OH)D was
not associated with TB phenotype, but the analysis was
limited by a low number of TB patients with extrapul-
monary disease.
Association between TB and low 25(OH)D in all subjects
and according to persistent hyperglycemia
Overall, the proportion of patients with a low 25(OH)D
was not statistically different in TB patients compared to
controls (25.8 % versus 31.0 %; p = 0.22). In the subgroup
of participants with persistent hyperglycemia (i.e. likely
true diabetic patients), baseline 25(OH)D tended to be
lower in TB patients than in controls (mean (±SE)
80.9 nmol/l ±6.4 versus 88.8 nmol/l ± 4.8; p = 0.33) and
the proportion of patients with low baseline 25(OH)D
tended to be greater (50 % versus 29.7 %; p = 0.20; Fig. 3).
In other words, unadjusted analysis suggests an asso-
ciation of low 25(OH)D with TB status among parti-
cipants with persistent hyperglycemia.
In contrast, in patients without persistent hypergly-
cemia, 25(OH)D was higher in TB patients than in
controls, irrespective of the time point of vitamin D meas-
urement (mean (±SE) 95.0 (±2.2) versus 89.7 (±1.5); p =
0.05) and the proportion of patients with low 25(OH)D
tended to be lower (23.9 % versus 31.2 %; p = 0.10).
Neither low 25(OH)D nor persistent hyperglycemia
were associated with an increased risk of TB when
occurring in isolation. However, the combination of the
two factors was associated with a fourfold increase in
the odds of TB compared to patients without the two
risk factors. While this difference was not quite statisti-
cally significant (p = 0.08), the interaction of the two
factors was (adjusted OR (95 % CI): 12.42 (1.78−86.60);
Table 1 Characteristics at baseline of the case-control sample
TB patients
N = 167
Healthy controls
N = 358
N (%) or Mean (sd) p
Age 33.7 (10.7) 36.1 (13.0) 0.05
Male sex 95 (56.9) 191 (53.4) 0.45
History of smoking 25 (15.0) 90 (25.3) 0.008
Alcohol misuse 16 (9.6) 22 (6.2) 0.16
Socioeconomic status
Low 41 (24.6) 71 (19.9) 0.25
Medium 82 (49.1) 185 (52.0) 0.64
High 44 (26.4) 100 (28.1) 0.75
Mean daily sunshine hours
during the month of enrolment
7.9 (1.4) 7.9 (1.1) 0.08
Body Mass Index (kg/m2) 22.5 (4.2) 25.1 (5.1) <0.001
HIV infection 51 (30.7) 51 (14.3) <0.001
Previously known DM 5 (3.0) 2 (0.6) 0.02
Hyperglycemia at enrolment 38 (22.8) 37 (10.3) <0.001
Persistent hyperglycemia 12 (7.2) 37 (10.3) 0.33
25 hydroxyvitamin D deficiency 3 (1.8) 21 (5.9) 0.04
Low 25 hydroxyvitamin D 43 (25.8) 111 (31.0) 0.22
25 hydroxyvitamin D level
(nmol/l)
94.0 (26.9) 89.6 (26.9) 0.08
TB characteristics
TB symptoms >3 months 21 (12.6)
TB
Smear positive 136 (81.4)
Smear negative 27 (16.2)
Extrapulmonary 4 (2.4)
Cavity on X-ray 86 (52.8)
Abbreviations and definitions: TB tuberculosis, Alcohol misuse ≥3 drinks per
day or ≥6 drinks per occasion, Socioeconomic status assessed with indicators
of scholar education, occupation and wealth ownership using factor analysis,
Persistent hyperglycemia presence of hyperglycemia at enrolment confirmed
at follow up (measure of glycemia repeated among patients with tuberculosis
only), Low vitamin D <75 nmol/l, Vitamin D deficiency <50 nmol/l.
Hyperglycemia fasting capillary glucose >6 mmol/l and/or 2-hCG >7.7 mmol/l,
TB symptoms >3months >3months duration of tuberculosis symptoms.
P values were calculated using the Wilcoxon-Mann-Whitney test for continuous
variables and chi-square tests for categorical variables
Fig. 2 Categorical scatter plot representing the longitudinal
evolution of vitamin D level between baseline and follow-up. Bars
represent the 25th percentiles, the median and the 75th percentiles.
The difference between enrolment and follow-up was tested with
Wilcoxon-Mann-Whitney test. Abbreviation: TB: tuberculosis
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pinteraction = 0.01; Table 3). Additional adjustment for the
month of recruitment had no effect on the results
presented in Table 3.
The interaction was not significant when using the
continuous value of 25(OH)D (adjusted OR (95 % CI):
0.97 (0.93−1.01); pinteraction = 0.09).
Discussion
In this black sub-Saharan equatorial population, we
provide novel evidence for the association between low
25(OH)D and TB among persons with persistent hyper-
glycemia, irrespective of HIV status. In contrast, 25(OH)D
levels were higher in TB cases compared to controls in
normoglycemic participants. The longitudinal design of
this study reinforces the validity of our findings as it
makes possible to differentiate between persons with only
transient hyperglycemia possibly related to the acute
phase of inflammation versus participants with persistent
hyperglycemia who are likely truly diabetic patients. ().
The associations between low vitamin D status and
DM, low vitamin D status and TB as well as TB and DM
have been demonstrated in many studies. These data
point to vitamin D as a potential mediator in the link
between DM and TB which is consistent with our results
[10]. Our data are also concordant with an Indian study
showing that the prevalence of severe vitamin D insuffi-
ciency (<25 nmol/L) was higher among TB patients with
DM compared to those without DM [11]. However, in
our study, the definition of low vitamin D was different
(<75 nmol/L) as most participants had a high 25(OH)D
concentration. The absence of an association between
DM and 25(OH)D among healthy controls may be
explained by the low statistical power related to the low
numbers of diabetic patients. Our longitudinal study
underlines the limitations of studying the combined
Table 2 Factors associated with low 25 hydroxyvitamin D level among healthy controls and tuberculosis patients at enrolment
TB patients (N = 167) Healthy controls (N = 358)
Low 25(OH)D level Normal 25(OH)D level Low 25(OH)D level Normal 25(OH)D level
N = 43 (25.7 %) N = 124 (74.3 %) N = 111 (31.0 %) N = 247 (69.0 %)
N (%) or Mean (sd) N (%) or Mean (sd) p N (%) or Mean (sd) N (%) or Mean (sd) p
Age 35.1 (12.0) 33.3 (10.2) 0.53 35.5 (12.4) 36.4 (13.3) 0.79
Male sex 20 (46.5) 75 (60.5) 0.11 46 (41.4) 144 (58.8) 0.002
History of smoking 4 (9.3) 21 (16.9) 0.23 25 (22.5) 65 (26.8) 0.40
Alcohol misuse 0 (0) 7 (5.7) 0.11 3 (2.7) 19 (7.7) 0.07
Socioeconomic status
Low 11 (25.6) 30 (24.2) 0.84 17 (15.3) 54 (22.2) 0.2
Medium 22 (51.2) 60 (48.4) 0.86 57 (51.4) 127 (52.3) 1
High 10 (23.3) 34 (27.4) 0.84 37 (33.3) 62 (25.5) 0.13
Mean daily sunshine hours during the
month of enrolment
8.2 (1.2) 7.9 (1.4) 0.26 7.9 (1.0) 7.9 (1.1) 0.22
Body mass index (kg/m2) 19.8 (3.1) 20.4 (3.9) 0.54 25.8 (5.5) 24.9 (4.8) 0.11
HIV infection 12 (27.9) 39 (31.7) 0.64 6 (5.4) 45 (18.4) 0.001
Previously known for DM 4 (9.3) 1 (0.8) 0.005 0 (0) 2 (0.8) 0.34
Hyperglycemia at enrolment 9 (20.9) 29 (23.4) 0.74 11 (9.9) 26 (10.5) 0.86
Persistent hyperglycemia 6 (14.0) 6 (4.8) 0.05
TB characteristics
TB symptoms >3 months 8 (18.6) 13 (10.5) 0.17
TB
Smear positive 36 (83.7) 100 (80.7) 0.82
Smear negative 6 (14.0) 21 (16.9) 1
Extrapulmonary 1 (2.3) 3 (2.4) 1
Cavity on X-ray 20 (48.8) 66 (54.1) 0.56
Abbreviations and definitions: 25(OH)D 25 hydroxyvitamin D, Low vitamin D level <75 nmol/l, Alcohol misuse ≥3 drinks per day or ≥6 drinks per occasion,
Socioeconomic status assessed with indicators of scholar education, occupation and wealth ownership using factor analysis, DM diabetes, Persistent hyperglycemia
presence of hyperglycemia at enrolment and at follow up (measure of glycemia repeated among patients with tuberculosis only). Hyperglycemia fasting capillary
glucose >6 mmol/l and/or 2-hCG >7.7 mmol/l, TB symptoms >3months >3 months duration of tuberculosis symptoms before diagnosis.
P values were calculated using the Wilcoxon-Mann-Whitney test for continuous variables and chi-square tests for categorical variables
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impact of circulating glucose and 25(OH)D on TB in a
cross-sectional manner only (i.e. based on data at baseline
only). At the time of diagnosis of active TB, the inflam-
mation status can influence hyperglycemia (stress-induced
hyperglycemia) and likely also 25(OH)D levels (e.g.
through induction of 25(OH)D metabolism or transient
changes in the blood levels of proteins bound to 25(OH)D)
[19, 27, 28]. Hence, cross-sectional studies may miss the
importance of DM (persistent hyperglycemia) in the asso-
ciation between TB and vitamin D status [19]. Consistent
with two other studies, 25(OH)D level increased during TB
treatment in our study, despite the described lowering
effect of isoniazid and rifampicin on blood vitamin D
[29–31]. The improved vitamin D status during TB
treatment may be related to greater sun exposure and
dietary intake of vitamin D during recovery. However,
Fig. 3 Longitudinal evolution of vitamin D level and selected variables according to tuberculosis status and hyperglycemia at baseline and
follow-up. Abbreviation: TB: tuberculosis. 25(OH)D concentration and 25(OH)D status were compared according to TB status after stratification by
persistent hyperglycemia using P values calculated by the Wilcoxon-Mann-Whitney test for continuous variables and chi-square tests for
categorical variables. * p = 0.33; # p = 0.20; £ p = 0.05; ¥ p = 0.11
Table 3 Association with tuberculosis in different patients’ categories according to vitamin D and glycemic status
Association with tuberculosis
Adjusted OR (95 % CI)a P value
Normal 25 hydroxyvitamin D level and absence of persistent hyperglycemia Ref. Ref.
Low 25 hydroxyvitamin D level and absence of persistent hyperglycemia 0.70 (0.41–1.20) 0.20
Normal 25 hydroxyvitamin D level and persistent hyperglycemia 0.46 (0.15–1.44) 0.18
Low 25 hydroxyvitamin D level and persistent hyperglycemia 4.0 (0.86–18.54) 0.08
Interaction factor between low 25 hydroxyvitamin D and persistent hyperglycemia: adjusted OR (95%CI) 12.42 (1.78–86.60); pinteraction = 0.01
aAdjusted for age, sex, body mass index, socioeconomic status, mean daily sunshine hours during the month of enrolment and HIV status.
Low vitamin D level <75 nmol/l, Persistent hyperglycemia presence of hyperglycemia at enrolment confirmed at follow up (measure of glycemia repeated
among patients with tuberculosis only).
Adjusted odds ratios and p values were calculated using multivariate logistic regression
Boillat-Blanco et al. BMC Infectious Diseases  (2016) 16:626 Page 6 of 9
results related to 25(OH)D have to be interpreted
carefully, as 25(OH)D mainly reflects protein-bound
vitamin D and may not represent the level of free
active form of vitamin D. During inflammation, similarly to
levels of several other blood acute-phase proteins, the
concentration of albumin decreases and might modify
25(OH)D result [27], while one study showed no change in
blood VDBP during the first 8 weeks of TB treatment [28].
Further studies should examine the relation between TB,
diabetes and vitamin D based on levels of free vitamin D.
The importance of low blood levels of vitamin D as
a risk factor for the development of TB was suggested
in a prospective cohort study conducted among HIV-
infected adults in Tanzania [32]. Several case control
studies also reported a lower blood 25(OH)D in TB
patients compared to control groups [33, 34]. How-
ever, consistent with a large study conducted in Mwanza,
Tanzania, we observed an increased 25(OH)D among TB
patients compared to healthy controls, particularly after
treatment of TB [29]. Also, contrary to many studies
elsewhere, mean 25(OH)D was in the normal range in the
Tanzanian studies, possibly because of higher vitamin D
levels in a tropical country with high exposure to UVB
compared to countries remote of the Equator, which may
have limited the potential impact of low 25(OH)D on TB
to only the group of diabetic patients who had lower
25(OH)D levels [35]. Indeed, vitamin D deficiency varies
between studies conducted in Africa, ranging from 4.3 %
in Tanzania to 62.7 % in South Africa [33].
Our study has several strengths. First, the longitudinal
design allowed assessing the association between TB,
DM and vitamin D after resolution of inflammation,
which influences glycemic status. Indeed, many TB
patients with hyperglycemia at baseline have a normal
glycemia after TB treatment which suggests that many
cross-sectional studies on the association between TB
and DM probably overestimate the increased TB risk
associated with DM. The study population was well
defined and the patients categorized according to WHO
recommendations. Our study also has limitations. First,
we performed the measurement of total 25(OH)D and
not its active form (1,25(OH)2D) [7]. TB diagnosis was
based on NTLP guidelines and smear results rather than
culture or GenXpert. However, the study was conducted
under the real case scenario of TB treatment in this
population. Fasting and 2-h glucose were assessed on
capillary whole blood using a point-of-care test and not
in venous blood. However, we used a plasma-calibrated
glucometer the accuracy of which conformed to the
International Standardization Organization guidelines
[25]. Another limitation of our study is that healthy
controls did not have a follow-up assessment of their
glycemic status. However, we did not expect a temporal
modification of DM status over 5 months’ follow-up in
the general population as we included only participants
who did not present any acute infection or major trauma
within the last 3 months. We used persistent hypergly-
cemia as a proxy of DM in TB patients to exclude
patients with stress hyperglycemia secondary to TB
infection. This definition may have missed some DM
patients who had improvement of their glycemic status
by changing their lifestyle during the follow-up period.
However, very few patients (N = 3) went to the DM
clinic and had lifestyle counselling and it is unlikely that
it significantly contributed to our results. Vitamin D
deficiency was recently identified as a probable risk
factor for extrapulmonary TB [36]. However, the number
of TB patients with this phenotype was very low in our
study and did not allow any subgroup analysis. The
impact of 25(OH)D level on TB outcome is controversial
and adjunctive vitamin D may improve TB outcome in
subgroups of patients only [15, 18, 31, 37]. Unfor-
tunately, we did not have the power to look at the effect
of the interaction between low 25(OH)D and persistent
hyperglycemia on TB outcome.
Conclusions
In this equatorial population with a high mean 25(OH)D
concentration (91 nmol/L), a low blood level of
25(OH)D (<75 nmol/L) seems to increase the risk of TB
only in the context of persistent hyperglycemia. Diabetic
patients might be an appropriate target for vitamin D
supplementation to improve TB outcome or prevent ac-
tive TB, but the benefit of such interventions requires
confirmation through randomized controlled trials.
Additional files
Additional file 1: Figure S1. Longitudinal evolution of glycemic status
among tuberculosis patients between enrolment (left bar) and follow up
(right bar). Abbreviation: pre-DM: pre-diabetes, defined as fasting capillary
glucose between 6.1 and 7 mmol/l and/or 2-h capillary glucose between
7.8 and 11.0 mmol/l; DM: diabetes, defined as fasting capillary glucose
>7 mmol/l and/or 2-h capillary glucose >11.0 mmol/l, according to WHO
recommendation. (JPG 46 kb)
Additional file 2: Table S1. Characteristics of the TB patients with and
without follow-up. (DOCX 15 kb)
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1,25(OH)2D: 1,25-Dihydroxyvitamin D; 2h-CG: 2-h capillary glucose after
standard oral glucose tolerance test; 25(OH)D: 25-hydroxyvitamin D; 95 %
CI: 95 % Confidence interval; aOR: Adjusted odds ratio; BMI: Body mass index;
DM: Diabetes mellitus; FCG: Fasting capillary glucose; NTLP: National
tuberculosis and leprosy control programme; OGTT: Oral glucose tolerance
testing; pre-DM: Pre-diabetes; SD: Standard deviation; SES: Socio-economic
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